Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BMS SCLC CA184156: Inclusion/Exclusion Criteria Inclusion Criteria 1. Signed Written Informed Consent (willing and able to provide informed consent). 2. Subjects with SCLC documented by histology or cytology from brushing, washing, or needle aspiration of a defined lesion but not from sputum cytology alone. 3. Subjects must present extensive stage disease (VALG classification). 4. Eastern Cooperative Oncology Group (ECOG) performance status < 1. 5. Accessible for treatment and follow-up. Subjects enrolled in this trial must be treated at the participating centers. 6. Men and Women > 18 years of age. 7. Women of child bearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug in such manner that the risk of pregnancy is minimized. See section 3.3.3 for the definition of WOCBP. 8. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of investigational product. 9. Women must not be breastfeeding. 10. Sexually active fertile men must use effective birth control if their partners are WOCBP. Exclusion Criteria 1. CNS metastases unless non-symptomatic (ie, no neurological deficit, epilepsy or other signs and symptoms typical of CNS metastases), and not requiring treatment with steroids or anticonvulsant medications. In addition, if treated with radiation therapy, CNS mets must be stable with no evidence of progression on scans for at least 30 days from the initial radiologic diagnosis of CNS mets. 2. Malignant pleural effusion that is recurrent despite appropriate supportive care. 3. Documented history of severe autoimmune or immune mediated symptomatic disease that required prolonged (more than 2 months) systemic immunosuppressive (ie, steroids) treatments such as: Ulcerative colitis and Crohn’s disease, Rheumatoid arthritis, systemic progressive sclerosis (scleroderma), Systemic Lupus Erythematous, Autoimmune vaculitis (ie, Wegener’s Granulomatosis). 4. Subjects with a history of toxic epidermal necrolysis (TEN). 5. Interstitial pneumonia or pulmonary fibrosis. 6. Paraneoplastioc autoimmune syndrome. 7. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent or completing questionnaires. 8. Serious uncontrolled medical disorder that, in the opinion of the investigator, would impair the ability of the subject to receive protocol therapy. 9. Prior malignancy, active within 5 years, except for locally curable cancers that have been apparently cured and need no subsequent therapy, such as basal or squamous cell skin cancer, superficial bladder cancer of carcinoma in situ of the cervix or breast. 10. HIV, active Hepatitis B, or active Hepatitis C infection, based on testing performed during the CA184156 screening period. In the event of a positive HIV or anti-HCV antibody test, results of confirmatory testing must be awaited before randomization. 11. Prior systemic therapy of loco-regional surgeries are allowed if performed at least 3 weeks prior to the start of study therapy. 12. Subjects with > Grade 2 peripheral neuropathy. 13. Inadequate hematologic function defined by: 14. Absolute neutrophil count (ANC), 1,500 mm3. 15. Platelet count, 100,000/ mm3. 16. Hempoglobin level, 9 g/dL. 17. Inadequate hepatic function: 18. Total bilirubin level > 2.5 times the ULN. 19. AST and ALT levels > 2.5 times the ULN. 20. Inadequate renal function defined as calculated creatinine clearance < 50 ml/min based on the standard Cockroft and Gault formula. 21. Sodium (Na) < 130 mmol/l. 22. Chronic use of immune-suppressive drugs (ie. Corticosteroids used in the management of cancer or non-cancer related illnesses). Use of corticosteroids are allowed if used as premedication for chemotherapy administration or on-study management of an AE. 23. Any non-oncology vaccine therapy used for prevention of infectious disease (for up to 4 weeks prior to or after any dose of blinded study drug). 24. Any immunotherapy for the treatment of cancer. 25. Prior treatment with any inhibitor or agonist of T-cell co-stimulation. 26. Prisoners or subjects who are involuntary incarcerated. 27. Subjects who are compulsorily detained for treatment of either a psychiatrist or physical (eg, infectious disease) illness. *Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and to ensure that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.